SCHEMBL1967464

SCHEMBL1967464

Cc1cc[c]c(Cl)c1C#N

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 7/20 0.33
ALDH1A1 P00352 4/20 0.33
NPSR1 Q6W5P4 3/20 0.33
HPGD P15428 2/20 0.33
PPARG P37231 1/20 0.33
STAT3 P40763 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NR2E3 Q9Y5X4 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
KMT2A Q03164 3/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 2/20 0.31
HSD17B10 Q99714 3/20 0.31
USP2 O75604 1/20 0.31
AR P10275 1/20 0.31
MEN1 O00255 2/20 0.31
MAPT P10636 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14660831 0.78 ALDH1A1 (0.35) CYP1A2CYP2C19L3MBTL1KDM4EALDH1A1
SCHEMBL7106518 0.78 CYP1A2 (0.37) CYP1A2CYP2C19KDM4EALDH1A1HPGD
SCHEMBL8880450 0.75 KDM4E (0.35) L3MBTL1KDM4EALDH1A1NPSR1HPGD
SCHEMBL5327680 0.75 KDM4E (0.36) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL7975208 0.74 CYP1A2 (0.46) CYP1A2CYP2C19L3MBTL1KDM4EALDH1A1
SCHEMBL31050110 0.74 CYP1A2 (0.46) CYP1A2CYP2C19L3MBTL1KDM4EALDH1A1
SCHEMBL11415446 0.72 CYP1A2 (0.33) CYP1A2CYP2C19KDM4E
SCHEMBL1967465 0.71 KDM4E (0.35) CYP1A2CYP2C19L3MBTL1KDM4EALDH1A1
SCHEMBL1969746 0.70
SCHEMBL2347098 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334683-B1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS MSD ITALIA SRL (IT) 2017-03-22 EP disclosed
US-8470823-B2 Saturated bicyclic heterocyclic derivatives as SMO antagonists INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2013-06-25 US disclosed
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS Instituto di Ricerche di Biologia Molecolare P. Ang 2011-07-28 US disclosed
EP-2334683-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) 2011-06-22 EP disclosed
WO-2010023480-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183989-A1 SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS SMO, SHH, GLI1 CYP1A2 2635/4885CYP2C19 4185/4885L3MBTL1 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.